Pro Medicus Limited (ASX: PME)
The healthcare sector company, Pro Medicus Limited (ASX: PME) seems to be on investors’ radar as the stock price has almost doubled itself in the past 12 months. PME has returned approximately a 88.01% yield in a year, outlining a price leap from $8.416 a year ago to current $16.400 as at 15 March 2019.
In today’s trading session, the stock edged up by 2.308% to last trade near to its 52-week high at $16.400 on 15 March 2019. After watching today’s trade, it looks evident that the stock may soon surpass its 52-week high of $16.540. Price to Earnings multiple stood at 98.650 x with a market capitalisation of $1.66 billion.
The optimism seems to be driven by the company’s solid fundamentals recently proved in the interim result. Pro Medicus declared 184.3% growth in NPAT of $9.1 million for the six months ended 31 December 2018, compared to the PCP.
The Group reported the half-year revenue to $25.3 million, reflecting 59.4% improvement on 1H FY18. On geographical segment front, it achieved higher revenue in its all key jurisdictions including 40% rise in North America, 30% in Australia and as massive as a 204% increase in Europe.
With sufficient cash reserves and debt-free balance sheet, Pro Medicus declared a special dividend of 2.5 cents per share along with the interim dividend of 3.5 cents per share payable on 22 March 2019. The fully franked special dividend is scheduled to be paid on 17 May 2019 to the shareholders present on the company’s registry as on the record date of 13 March 2019.
As at 31 December 2018, Pro Medicus cash reserves stood at $24.7 million.
CSL Limited (ASX: CSL)
Another high performing health-care stock CSL Limited (ASX: CSL) has given massive returns in the last 12 months. It translates a long-term positive momentum maintained by the stock on the Australian Securities Exchange with as high as 173.63% return in the past 5 years.
CSL achieved significant growth in the half year ended 31 December 2018 as its revenues from continuing operations increased by 8.6% to US$4.5 billion. Wherein its bottom line touched 6.8% growth, reporting a net profit after tax for the period attributable to members of US$1.2 billion compared to the previous corresponding period.
The growth in company’s half-year revenue also reflects the seasonal nature of influenza as the Seqirus’ total revenue grew by 21% to US$949 million driven largely by increased sales of seasonal influenza vaccines.
The Board declared the interim dividend of 85.0 cents per share, up from previous corresponding period dividend of 79.0 cents. This dividend relating to the half-year ended 31 December 2018 is scheduled to be paid on 12 April 2019 with the record date of 14 March 2019.
Over the past 12 months, CSL has returned the yield of 19.41%, reflecting the surge of 8.90% in the past three months. The stock last traded at $195.930 while its 52-week high sits at $232.690 as at 15 March 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.